Senior Researcher in Molecular Biology, working in Hematology Service, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsies are less risky, painful, and costly, and are increasingly being used to analyze biomarkers in liquid samples, such as blood. Recent advances in genomic technologies such as digital PCR (dPCR) and next generation sequencing (NGS) have enabled researchers to more comprehensively detect and study cancer related mutations, even when they are very rare.
In this panel of key opinion leaders in the liquid biopsy space, we dive deeper into the the impact of genomics and genomics technologies on the current and future of liquid biopsy clinical research and cancer management.
At Thermo Fisher Scientific we are committed to developing robust sample preparation solutions for cell-free nucleic acids and highly sensitive liquid biopsy assays utilizing both digital PCR (dPCR) and targeted next-generation sequencing (NGS) to enable cancer driver identification, serial monitoring, and recurrence detection.
Senior Researcher in Molecular Biology, working in Hematology Service, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria
Senior Director and General Manager of Digital PCR, Thermo Fisher Scientific
Head of the Department of Molecular Medicine and Research, Koo Foundation Sun Yat-Sen Cancer Center
Head of Research at the Belfer Center for Applied Cancer Science, Dana Faber Cancer Institute (DFCI)
Vice President and Global Head of Medical Affairs for the Clinical Sequencing Oncology Division, Thermo Fisher Scientific
Head of Molecular Oncology Laboratory, General University Hospital Research Foundation
Codirector, Genetics of solid and hereditary tumors, University of Navarra
Translational Oncology Research Unit, RCSS Regina Elena National Cancer Institute
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsies are less risky, painful, and costly, and are increasingly being used to analyze biomarkers in liquid samples, such as blood. Recent advances in genomic technologies, such as digital PCR (dPCR) and next-generation sequencing (NGS), have enabled researchers to more comprehensively detect and study cancer-related mutations, even when they are very rare.
With this panel of key opinion leaders in the liquid biopsy space, we dive deeper into the impact of genomics and genomics technologies on the current and future of liquid biopsy clinical research and cancer management. At Thermo Fisher Scientific we are committed to developing robust sample preparation solutions for cell-free nucleic acids and highly sensitive liquid biopsy assays utilizing both dPCR and targeted NGS to enable cancer driver identification, serial monitoring, and potential recurrence detection.